China Infliximab Market Research Report 2021-2025 –


DUBLIN–(BUSINESS WIRE)–The “Chinese Infliximab Market Investigation Report 2021-2025” report has been added to from offer.

Infliximab is a chimeric human-mouse IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-A) (composed of a human IgG1 constant region and a mouse variable region).

It is used to treat various autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, infliximab entered the Chinese market. As of 2020, Janssen Biologics BV is the sole manufacturer in the Chinese infliximab market.

According to the market researcher, since infliximab entered the Chinese market in 2007, its sales have been on an upward trend. However, sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the high price. After the inclusion of infliximab in the national medical insurance in 2019, sales increased by approximately 18.86% in 2020 and reached CNY 213.7 million. The CAGR for infliximab is approximately 14.65% from 2016 to 2020.

The analyst analyzes that the sales of Infliximab will keep a growth trend from 2021 to 2025 due to the price reduction. After infliximab’s patent expired, more biosimilar drugs appeared on the market. In China, three companies have already submitted applications for Infliximab in 2019 and 2020.

Therefore, over the next few years, the market share of Janssen Biologics BV will gradually decrease. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of infliximab.

Topics Covered:

  • The impact of COVID-19 on the Chinese infliximab market

  • Infliximab sales value in China 2016-2020

  • Competitive landscape of Chinese infliximab market

  • Infliximab price in China

  • Infliximab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese infliximab market

  • China infliximab market outlook from 2021 to 2025

Main topics covered:

1 Relevant concept of infliximab

1.1 Indications for infliximab

1.2 Development of infliximab in China

1.3 Government approval of infliximab in China

1.4 The impact of COVID-19 on infliximab sales in China

2 China Infliximab Sales, 2016-2020

2.1 Infliximab Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Infliximab Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China Infliximab Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Infliximab Key Manufacturers in China, 2016-2020

3.1 Infliximab Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Janssen Biologics BV

3.2.1 Company Profile

3.2.2 REMICADE (Janssen Infliximab) Sales in China

4 infliximab prices for different manufacturers in China, 2020-2021

4.1 Janssen Biologics BV (REMICADE)

5 China Infliximab Drug Market Outlook, 2021-2025

5.1 Influencing Factors of China Infliximab Market Development

5.1.1 The impact of COVID-19 on the Chinese infliximab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

Companies cited

For more information on this report, visit


Comments are closed.